WBB Securities Initiates Coverage on Jazz Pharmaceuticals (JAZZ) with a Buy
JAZZ Hot Sheet
Rating Summary:9 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
WBB Securities initiates coverage on Jazz Pharmaceuticals (Nasdaq: JAZZ) with a Buy rating. PT $15.
To see all the upgrades/downgrades on shares of JAZZ, visit our Analyst Ratings page.
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
To see all the upgrades/downgrades on shares of JAZZ, visit our Analyst Ratings page.
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Jazz Pharmaceuticals (JAZZ) at Outperform
- Goldman Sachs Cuts Numbers on Tiffany & Co. (TIF) after Weak Q1, Guidance
- Wunderlich Securities Starts Pool Corp (POOL) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
